PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center PowerGlobeNewsWire · 2 days ago
Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)Defense World · Oct 12, 2026
PRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power OptimizationGlobeNewsWire · Sep 16, 2026
PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decrease in Short InterestDefense World · Sep 11, 2026
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading PlatformGlobeNewsWire · Sep 9, 2026
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy BusinessGlobeNewsWire · Sep 3, 2026PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations.